Skip to Main Content

Alex Azar’s job hop from drugmaker Eli Lilly to the Trump administration reflects ever-deepening ties between the pharmaceutical industry and the federal government.

A Kaiser Health News analysis shows that hundreds of people have glided through the “revolving door” that connects the drug industry to Capitol Hill and to the Department of Health and Human Services.


Azar was confirmed Wednesday as  HHS secretary, joining other former drug industry alumni in top positions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!